Cervical Intraepithelial Neoplasia (CIN) is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Cervical Intraepithelial Neoplasia (CIN) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Cervical Intraepithelial Neoplasia (CIN) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cervical Intraepithelial Neoplasia (CIN) overview
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is characterized by the abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women ages 25 to 35. Most cases of cervical dysplasia are caused by human papillomavirus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge, and low back pain.
For a complete picture of PTSR and LoA scores for drugs in Cervical Intraepithelial Neoplasia (CIN), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
